Becton, Dickinson and Company $BDX Shares Purchased by Yousif Capital Management LLC

Key Points

• Yousif Capital Management increased its BDX stake by 19.3% in the third quarter, bringing its holdings to 69,438 shares valued at approximately $12.4 million. Institutional investors collectively own 86.97% of the company.
• BD reported quarterly earnings of $3.23 per share, beating estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• BD pays a quarterly dividend of $1.05, or $4.20 annually, for a 2.1% yield. Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $185.07.

Yousif Capital Management LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 19.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,438 shares of the medical instruments supplier's stock after acquiring an additional 11,257 shares during the period. Yousif Capital Management LLC's holdings in Becton, Dickinson and Company were worth $12,429,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. lifted its stake in shares of Becton, Dickinson and Company by 17.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier's stock worth $14,715,000 after acquiring an additional 14,077 shares during the period. Northside Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 18.3% in the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock valued at $9,280,000 after acquiring an additional 9,494 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 35.0% during the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier's stock worth $6,923,000 after acquiring an additional 11,414 shares during the period. Beverly Hills Private Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth about $3,353,000. Finally, Wealthfront Advisers LLC purchased a new position in Becton, Dickinson and Company during the second quarter worth about $2,567,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.7%

Shares of NYSE BDX opened at $198.96 on Friday. The stock has a market capitalization of $54.82 billion, a price-to-earnings ratio of 59.93, a price-to-earnings-growth ratio of 13.41 and a beta of 0.21. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The firm has a 50-day moving average price of $185.41 and a 200 day moving average price of $165.10. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The firm's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company's stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 6,906 shares of company stock valued at $1,265,855. Insiders own 0.40% of the company's stock.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Jefferies Financial Group reiterated a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. UBS Group started coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price for the company. Finally, Zacks Research raised Becton, Dickinson and Company from a "hold" rating to a "strong-buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $185.07.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.